IQVIA Holdings Inc. $IQV Shares Sold by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. lowered its position in IQVIA Holdings Inc. (NYSE:IQV) by 4.9% during the third quarter, Holdings Channel.com reports. The fund owned 80,735 shares of the medical research company’s stock after selling 4,167 shares during the quarter. Jefferies Financial Group Inc.’s holdings in IQVIA were worth $21,706,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in IQVIA during the second quarter worth about $2,811,292,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of IQVIA by 9.0% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company’s stock valued at $315,772,000 after purchasing an additional 134,997 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of IQVIA by 4.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,657,696 shares of the medical research company’s stock valued at $282,657,000 after purchasing an additional 66,643 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of IQVIA during the 2nd quarter worth about $240,911,000. Finally, Bank of America Corp DE purchased a new stake in shares of IQVIA during the 2nd quarter worth about $235,551,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, September 12th. Stifel Nicolaus boosted their price objective on shares of IQVIA from $276.00 to $303.00 and gave the stock a “buy” rating in a research note on Wednesday, October 14th. Robert W. Baird increased their price objective on shares of IQVIA from $324.00 to $328.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 27th. Truist Financial raised their target price on shares of IQVIA from $329.00 to $346.00 and gave the company a “buy” rating in a research note on Wednesday, October 28th. Finally, Barclays raised their target price on shares of IQVIA from $275.00 to $300.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $294.21.

Insider Activity

In other news, insider James G. Berkshire sold 2,668 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the transaction, the insider directly owned 10,890 shares of the company’s stock, valued at approximately $2,845,883.70. The trade was a 19.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.70% of the stock is owned by corporate insiders.

IQVIA Price Performance

IQV stock opened at $274.73 on Thursday. The firm has a market cap of $45.28 billion, a P/E ratio of 33.38, a price-to-earnings-growth ratio of 2.44 and a beta of 1.16. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.83 and a current ratio of 0.83. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $284.50. The stock has a 50-day simple moving average of $267.53 and a 200-day simple moving average of $211.60.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, October 27th. The medical research company reported $3.34 EPS for the quarter, topping the consensus estimate of $3.26 by $0.08. The firm had revenue of $4.43 billion for the quarter, compared to analyst estimates of $4.37 billion. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. IQVIA’s revenue for the quarter was up 8.0% on a year-over-year basis. During the same period in the previous year, the company posted $3.00 EPS. On average, equities analysts predict that IQVIA Holdings Inc. will post 11.53 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.